

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Noriaki Ishida, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<http://www.daiichisankyo.com>

**Daiichi Sankyo Selected for Japanese Government's Second Initiative to Build Production
Facilities for Biopharmaceuticals**

TOKYO, Japan (July 12, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) has announced that it has been approved for the Japanese Ministry of Economy, Trade and Industry's production facility building grant, which is part of the Ministry's second production facility building initiative. Daiichi Sankyo will apply the grant toward the expansion of production facilities for biopharmaceuticals.

Daiichi Sankyo is planning an investment of approximately 2.9 billion yen to expand clinical trial and initial commercialization production facilities for biopharmaceuticals at the Tatebayashi Biopharmaceuticals Center (located in Chiyoda-cho, Gunma Prefecture). The grant from the Japanese government to be received by Daiichi Sankyo will cover a portion of the construction cost of the new production facilities.

In order to fully support this national production facility building initiative, Daiichi Sankyo will strengthen the internal production platform for biopharmaceuticals, including antibody drugs, leading directly to the introduction of biopharmaceutical and biosimilar therapies in the future and promoting the further evolution of the hybrid business model.

###